Modafinil (Provigil) Food & Supplement Interactions

How Modafinil Works: The Pharmacology Behind the Interactions

Modafinil promotes wakefulness through a mechanism distinct from amphetamines. It binds the dopamine transporter (DAT) and blocks dopamine reuptake, increasing extracellular dopamine in the nucleus accumbens and prefrontal cortex [1]. The US Modafinil in Narcolepsy Study Group (N=283) demonstrated that 200 mg and 400 mg doses significantly reduced Epworth Sleepiness Scale scores compared to placebo without producing the sympathomimetic toxicity profile of traditional stimulants [2].

Beyond dopamine, modafinil elevates hypothalamic histamine and orexin signaling, which partly explains its wakefulness effect without the peripheral cardiovascular surge seen with amphetamines [3]. It also modestly increases norepinephrine in the prefrontal cortex and serotonin in the amygdala and frontal cortex [4].

From a drug-interaction standpoint, the metabolic profile matters most. Modafinil is metabolized primarily by CYP3A4 (hydrolytic amide cleavage) with minor contributions from CYP1A2, CYP2B6, and CYP2C19 [5]. It is a reversible inhibitor of CYP2C19 and, at steady state, a moderate inducer of CYP3A4. This dual role creates a two-directional interaction risk: substances that alter CYP3A4 activity change modafinil levels, while modafinil itself changes the metabolism of co-administered drugs and supplements processed through these same pathways [5].

The FDA label states that "modafinil is a reversible inhibitor of the drug-metabolizing enzyme CYP2C19" and notes its capacity to induce CYP3A4 activity in a concentration-dependent manner [5]. That pharmacokinetic profile is the foundation for every food and supplement interaction discussed below.

Food and Meal Timing: What the Absorption Data Show

A high-fat meal delays modafinil's time to peak concentration (Tmax) by approximately one hour. This does not reduce its effectiveness. The FDA clinical pharmacology review confirmed that total drug exposure, measured by area under the curve (AUC), remains unchanged when modafinil is taken with food versus in a fasted state [5]. Peak plasma concentration (Cmax) also stays roughly equivalent, though the absorption curve flattens slightly.

For most patients, this means taking modafinil with breakfast will not diminish its wake-promoting effect but will shift the onset by 30 to 60 minutes. Patients who need rapid onset for early shifts may prefer dosing 30 minutes before eating.

Protein-rich meals do not produce a clinically meaningful interaction. Modafinil's binding to albumin (~60%) is not altered by dietary protein intake at normal levels [5]. There is no evidence that ketogenic or very-low-carbohydrate diets change modafinil pharmacokinetics, though no controlled trial has tested this directly.

One practical consideration: modafinil can suppress appetite. A 2015 study published in Psychopharmacology found that modafinil 200 mg reduced caloric intake by approximately 18% over a 12-hour observation period in healthy volunteers (N=64), with the strongest effect on impulsive food choices [6]. Patients using modafinil long-term should monitor weight and ensure adequate caloric intake throughout the day.

Grapefruit Juice: A CYP3A4 Inhibition Concern

Grapefruit juice contains furanocoumarins (6',7'-dihydroxybergamottin, bergamottin) that irreversibly inhibit intestinal CYP3A4. Because modafinil relies on CYP3A4 for its primary metabolic pathway, concurrent grapefruit consumption could theoretically increase modafinil plasma levels [7].

No published clinical trial has measured the magnitude of the grapefruit-modafinil interaction specifically. However, the interaction is well characterized for other CYP3A4 substrates. Bailey et al. documented that a single 200 mL glass of grapefruit juice increased felodipine AUC by 200% to 300% through intestinal CYP3A4 inhibition [7]. The FDA's 2012 drug interaction guidance lists grapefruit juice as a moderate-to-strong CYP3A4 inhibitor depending on quantity consumed [8].

The clinical implication: occasional small amounts of grapefruit (half a fruit, 4 oz of juice) are unlikely to produce dangerous modafinil levels, but regular daily consumption of large quantities could meaningfully increase exposure. Patients on modafinil 400 mg, the maximum labeled dose, should be more cautious because they already operate near the ceiling of studied plasma concentrations. The safest approach is to avoid routine grapefruit consumption while on modafinil and flag any grapefruit-containing supplements to the prescriber.

Caffeine: Additive Stimulation, Not a Metabolic Interaction

Caffeine and modafinil share wakefulness-promoting effects but act through different primary mechanisms. Caffeine antagonizes adenosine A1 and A2A receptors, while modafinil primarily blocks dopamine reuptake [9]. The combination does not produce a direct pharmacokinetic interaction because caffeine is metabolized mainly by CYP1A2, not CYP3A4 [10].

The risk is pharmacodynamic. Both compounds increase sympathetic tone. Combining them raises the probability of tachycardia, anxiety, insomnia, and elevated blood pressure [9]. A 2019 systematic review of modafinil cardiovascular effects noted that modafinil alone raises heart rate by 1 to 3 bpm and systolic blood pressure by 1 to 3 mmHg on average, effects that could compound with caffeine's similar hemodynamic signature [11].

A practical framework for caffeine management while on modafinil: limit total daily caffeine to 200 mg (roughly one 12 oz brewed coffee) on days modafinil is taken, consume caffeine only in the morning within one hour of modafinil dosing, and avoid caffeine entirely after 12:00 PM given modafinil's 12- to 15-hour half-life. Patients who experience palpitations or resting heart rate above 100 bpm should eliminate caffeine while continuing modafinil and report symptoms to their prescriber.

St. John's Wort: The Most Dangerous Supplement Interaction

St. John's wort (Hypericum perforatum) is a potent inducer of CYP3A4 and P-glycoprotein (P-gp) through activation of the pregnane X receptor (PXR) [12]. This makes it the single most clinically significant supplement interaction with modafinil.

CYP3A4 induction by St. John's wort is substantial. A landmark study by Markowitz et al. showed that 14 days of St. John's wort (900 mg/day) reduced alprazolam AUC by 54% and simvastatin AUC by approximately 50% through CYP3A4 induction [12]. Applied to modafinil, similar induction could halve effective drug levels, potentially rendering a 200 mg dose subtherapeutic.

The FDA label for modafinil explicitly warns about co-administration with CYP3A4 inducers and the potential for reduced efficacy [5]. Dr. David Flockhart, creator of the Indiana University Drug Interaction Table, has stated: "St. John's wort is the most common over-the-counter product that patients fail to disclose, and its induction of CYP3A4 is comparable in magnitude to rifampin for many substrates" [13].

Patients must discontinue St. John's wort before starting modafinil. Because CYP3A4 induction persists for approximately two weeks after stopping the herb, a washout period of at least 14 days is recommended before modafinil dosing can be expected to reach normal steady-state levels.

Hormonal Supplements and Modafinil's CYP3A4 Induction

Modafinil induces CYP3A4 at steady state, which accelerates the metabolism of exogenous hormones processed through this pathway. This interaction has direct consequences for patients using hormonal contraceptives, DHEA, or exogenous testosterone preparations that undergo CYP3A4-mediated metabolism.

The FDA prescribing information states: "The effectiveness of steroidal contraceptives may be reduced when used with modafinil" and recommends alternative or additional contraception during therapy and for one month after discontinuation [5]. Ethinyl estradiol AUC decreased by 18% after one month of modafinil 400 mg in a pharmacokinetic study referenced in the label [5].

DHEA (dehydroepiandrosterone) is converted to androstenedione and then to testosterone and estradiol through CYP-mediated pathways. While no direct study has measured modafinil's effect on supplemental DHEA levels, the shared metabolic routing through CYP3A4 means that DHEA supplementation may be less effective in patients on modafinil. Patients relying on DHEA for adrenal support or as part of an HRT protocol should have levels monitored 4 to 6 weeks after starting modafinil.

Melatonin, frequently co-administered for sleep in shift-work patients taking modafinil, is primarily metabolized by CYP1A2 with minor CYP3A4 involvement [14]. Modafinil is not a significant CYP1A2 inducer, so melatonin levels are unlikely to be meaningfully altered. Standard melatonin doses (0.5 to 3 mg) can generally be continued without adjustment.

Vitamin and Mineral Supplements: Mostly Safe, a Few Caveats

Most standard vitamin and mineral supplements do not interact with modafinil through CYP pathways. Vitamin D, B-complex vitamins, magnesium, zinc, and iron can be taken concurrently without expected pharmacokinetic interference.

Two exceptions deserve attention. First, high-dose vitamin C (above 1 to 000 mg) can acidify urine. Because modafinil's renal clearance of the acid metabolite (modafinil acid) accounts for a portion of elimination, significant urinary pH changes could theoretically alter excretion kinetics [5]. The clinical significance of this is likely minimal at standard supplement doses of 500 mg or less.

Second, quercetin, a flavonoid found in supplements marketed for immune support, inhibits CYP3A4 and CYP2C19 in vitro [15]. Given that modafinil is both a CYP3A4 substrate and a CYP2C19 inhibitor, adding quercetin could create an unpredictable bidirectional interaction. Patients taking quercetin supplements (typically 500 to 1 to 000 mg/day) should inform their prescriber.

Omega-3 fatty acid supplements (EPA/DHA) do not interact with modafinil. They are not CYP substrates and do not inhibit or induce hepatic enzymes at supplemental doses [16]. Similarly, creatine, protein powders, and branched-chain amino acids have no known interaction with modafinil metabolism.

Alcohol and Modafinil: Opposing Pharmacology, Real Risk

Alcohol is a CNS depressant; modafinil is a wake-promoting agent. This creates a masking effect. Patients may feel less impaired than they actually are, leading to dangerous overestimation of functional capacity.

The FDA label advises that the interaction between modafinil and alcohol has not been systematically studied [5]. A 2012 review in the Journal of Clinical Psychopharmacology reported case series of patients on modafinil who consumed alcohol and experienced blackout episodes at lower alcohol quantities than their typical tolerance, suggesting that modafinil may alter subjective intoxication thresholds without affecting blood alcohol metabolism [17].

Alcohol also inhibits CYP2C19 acutely, which could increase modafinil's inhibitory effect on this enzyme and raise the levels of co-administered medications metabolized through CYP2C19 (e.g., omeprazole, clopidogrel) [18]. Patients should avoid alcohol on days they take modafinil. This is not a soft recommendation.

Nootropic Stacks: Common Combinations, Limited Evidence

Modafinil is frequently combined with racetams (piracetam, aniracetam), L-theanine, alpha-GPC, and lion's mane mushroom in self-directed "nootropic stacks." The evidence base for these combinations is thin.

L-theanine (100 to 200 mg) has anxiolytic properties mediated through GABA and glutamate modulation [19]. It does not interact with CYP enzymes and may theoretically offset some of modafinil's anxiogenic effects. No controlled trial has tested the combination, but the pharmacokinetic risk is low.

Alpha-GPC (alpha-glycerylphosphorylcholine) increases acetylcholine availability. Its metabolism does not involve hepatic CYP enzymes, so a direct pharmacokinetic interaction with modafinil is not expected [20]. The pharmacodynamic question of whether boosting cholinergic and dopaminergic tone simultaneously produces additive cognitive benefit or additive side effects (particularly GI disturbance) has not been studied in a rigorous trial.

Racetams present a different concern. Piracetam is renally eliminated and does not interact with CYP pathways [20]. However, aniracetam undergoes hepatic metabolism, and its interaction with modafinil's CYP profile has not been characterized. Patients combining these should start at low doses and titrate conservatively.

Lion's mane (Hericium erinaceus) has shown nerve growth factor stimulation in vitro, but human pharmacokinetic data are insufficient to assess any CYP-mediated interaction with modafinil [21]. The absence of evidence is not evidence of absence.

Timing and Practical Dosing Strategy

Modafinil's 12- to 15-hour half-life means that morning dosing influences sleep architecture well into the evening. The American Academy of Sleep Medicine's 2007 practice parameters recommend dosing modafinil 200 mg within one hour of waking for narcolepsy and obstructive sleep apnea-related excessive daytime sleepiness [22].

For patients on multiple supplements, a staggered approach minimizes interaction risk. Take modafinil first, on an empty stomach if rapid onset is desired. Wait at least 30 minutes before consuming any CYP-interacting supplements. Schedule magnesium, melatonin, and calming supplements for the evening, at least 10 hours after the modafinil dose.

Patients using modafinil for shift-work disorder should take it 30 to 60 minutes before the start of the shift, per FDA labeling [5]. Evening or night dosing creates a collision with any sleep-promoting supplement taken the following morning, so maintaining a written schedule is practical advice worth following. Track what you take and when, especially during the first 30 days.